A cell-based assay for the detection of neutralizing antibodies against alemtuzumab

AIM: The humanized anti-CD52 monoclonal antibody alemtuzumab depletes lymphocytes and is currently used to treat relapsing multiple sclerosis. During treatment, anti-alemtuzumab antibodies may develop and reduce effective lymphocyte depletion in future treatment cycles. RESULTS: Alemtuzumab–Alexa Fl...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Liaqat, Saxena, Gauri, Jones, Meleri, Leisegang, Georgia R, Gammon, Luke, Gnanapavan, Sharmilee, Giovannoni, Gavin, Schmierer, Klaus, Baker, David, Kang, Angray S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2020
Materias:
Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177201/
https://www.ncbi.nlm.nih.gov/pubmed/32096651
http://dx.doi.org/10.2144/btn-2019-0122
Descripción
Sumario:AIM: The humanized anti-CD52 monoclonal antibody alemtuzumab depletes lymphocytes and is currently used to treat relapsing multiple sclerosis. During treatment, anti-alemtuzumab antibodies may develop and reduce effective lymphocyte depletion in future treatment cycles. RESULTS: Alemtuzumab–Alexa Fluor 488 conjugate binding to the CHO-CD52 cell surface was inhibited by anti-alemtuzumab antibodies. CONCLUSION: In this proof-of-concept study, a CHO-CD52 cell line has been developed and used to detect the presence of anti-alemtuzumab neutralizing antibodies. This platform provides the basis of an assay for routine screening of serum for neutralizing antibodies from patients treated with alemtuzumab.

Ejemplares similares